Skip to main content

Advertisement

ADVERTISEMENT

News

New Diabetic Foot Ulcer Treatment Gets Approvals

Origin, Inc (Princeton, NJ), a biotechnology company, announced that the US Food and Drug Administration approved the company’s request to conclude patient recruitment for the “GENESIS” Phase IIb trial of plasma-generated nitric oxide in patients with diabetic foot ulcers (DFUs). The conclusion follows positive interim analysis and evidence of healing in chronic DFUs in a sample of 83 randomized patients treated with topical application of plasma-generated nitric oxide. Data from the Phase IIb trial will allow the company to develop safety and effectiveness hypotheses needed to progress to Phase III trial design.

Click here for more information.

Advertisement

Advertisement